The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin production in these patients, based on positive results from the PROTECT phase 3 study involving over 900 patients. Tzield targets the autoimmune attack on insulin-producing beta cells, potentially changing the treatment approach for stage 3 T1D. Continued approval depends on further confirmatory studies, with ongoing trials like BETA-PRESERVE underway.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
